 It was developed at the Nigerian National Institute for Pharmaceutical Research and Development (NIPRD) (U.S. Patent # 5,800,819 - September 1, 1998).NIPRD is conducted a Phase III clinical trials in Nigeria which showed unclear benefit but have not been published as of 2010.In August 2002, a Nigerian subsidiary of the American company Xechem International, acquired the rights to Nicosan.